BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Darragh LB, Oweida AJ, Karam SD. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment. Front Immunol 2018;9:3154. [PMID: 30766539 DOI: 10.3389/fimmu.2018.03154] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Chipurupalli S, Ganesan R, Dhanabal SP, Kumar MS, Robinson N. Pharmacological STING Activation Is a Potential Alternative to Overcome Drug-Resistance in Melanoma. Front Oncol 2020;10:758. [PMID: 32477956 DOI: 10.3389/fonc.2020.00758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Masini C, Iotti C, De Giorgi U, Bellia RS, Buti S, Salaroli F, Zampiva I, Mazzarotto R, Mucciarini C, Vitale MG, Bruni A, Lohr F, Procopio G, Caffo O, Nole F, Morelli F, Baier S, Buttigliero C, Ciammella P, Timon G, Fantinel E, Carlinfante G, Berselli A, Pinto C. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur Urol 2021:S0302-2838(21)02040-6. [PMID: 34602312 DOI: 10.1016/j.eururo.2021.09.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
3 Vukadin S, Khaznadar F, Kizivat T, Vcev A, Smolic M. Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update. Biomedicines 2021;9:835. [PMID: 34356899 DOI: 10.3390/biomedicines9070835] [Reference Citation Analysis]
4 He Y, Liu T, Dai S, Xu Z, Wang L, Luo F. Tumor-Associated Extracellular Matrix: How to Be a Potential Aide to Anti-tumor Immunotherapy? Front Cell Dev Biol 2021;9:739161. [PMID: 34733848 DOI: 10.3389/fcell.2021.739161] [Reference Citation Analysis]
5 Liu S, Imani S, Deng Y, Pathak JL, Wen Q, Chen Y, Wu J. Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance. Onco Targets Ther 2020;13:6037-50. [PMID: 32606809 DOI: 10.2147/OTT.S256708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 Karam SD, Raben D. Radioimmunotherapy for the treatment of head and neck cancer. The Lancet Oncology 2019;20:e404-16. [DOI: 10.1016/s1470-2045(19)30306-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
7 Camara Planek MI, Silver AJ, Volgman AS, Okwuosa TM. Exploratory Review of the Role of Statins, Colchicine, and Aspirin for the Prevention of Radiation-Associated Cardiovascular Disease and Mortality. J Am Heart Assoc 2020;9:e014668. [PMID: 31960749 DOI: 10.1161/JAHA.119.014668] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
8 Taki S, Matsuoka K, Nishinaga Y, Takahashi K, Yasui H, Koike C, Shimizu M, Sato M, Sato K. Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity. J Immunother Cancer 2021;9:e003036. [PMID: 34725216 DOI: 10.1136/jitc-2021-003036] [Reference Citation Analysis]
9 Park SM, Youn JI. Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer. Arch Pharm Res 2019;42:560-6. [PMID: 31147902 DOI: 10.1007/s12272-019-01165-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
10 Wang H, Tan L, Dong X, Liu L, Jiang Q, Li H, Shi J, Yang X, Dai X, Qian Z, Dong J. MiR-146b-5p suppresses the malignancy of GSC/MSC fusion cells by targeting SMARCA5. Aging (Albany NY) 2020;12:13647-67. [PMID: 32632040 DOI: 10.18632/aging.103489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Gu X, Shi Y, Dong M, Jiang L, Yang J, Liu Z. Exosomal transfer of tumor-associated macrophage-derived hsa_circ_0001610 reduces radiosensitivity in endometrial cancer. Cell Death Dis 2021;12:818. [PMID: 34462422 DOI: 10.1038/s41419-021-04087-8] [Reference Citation Analysis]
12 Portella L, Scala S. Ionizing radiation effects on the tumor microenvironment. Semin Oncol 2019;46:254-60. [PMID: 31383368 DOI: 10.1053/j.seminoncol.2019.07.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
13 Gadwa J, Karam SD. Deciphering the Intricate Roles of Radiation Therapy and Complement Activation in Cancer. Int J Radiat Oncol Biol Phys 2020;108:46-55. [PMID: 32629082 DOI: 10.1016/j.ijrobp.2020.06.067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Modi C, Berim L, Isserow L, Malhotra J, Patel M, Langenfeld J, Aisner J, Almeldin D, Jabbour SK. Combining radiation therapy and immunotherapy for lung cancers: a narrative review. Shanghai Chest 2021;5:10. [PMID: 33521559 DOI: 10.21037/shc-20-66] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Benavente S, Sánchez-García A, Naches S, LLeonart ME, Lorente J. Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies. Front Oncol 2020;10:582884. [PMID: 33194719 DOI: 10.3389/fonc.2020.582884] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther 2020;5:60. [PMID: 32355263 DOI: 10.1038/s41392-020-0150-x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 70] [Article Influence: 30.0] [Reference Citation Analysis]
17 Demmers LC, Kretzschmar K, Van Hoeck A, Bar-Epraïm YE, van den Toorn HWP, Koomen M, van Son G, van Gorp J, Pronk A, Smakman N, Cuppen E, Clevers H, Heck AJR, Wu W. Single-cell derived tumor organoids display diversity in HLA class I peptide presentation. Nat Commun 2020;11:5338. [PMID: 33087703 DOI: 10.1038/s41467-020-19142-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
18 Fan X, Wu Q. Decoding Lung Cancer at Single-Cell Level. Front Immunol 2022;13:883758. [DOI: 10.3389/fimmu.2022.883758] [Reference Citation Analysis]
19 De Felice M, Tammaro M, Leopardo D, Ianniello GP, Turitto G. Moving towards the Future of Radio-Immunotherapy: Could We “Tailor” the Abscopal Effect on Head and Neck Cancer Patients? Immuno 2021;1:410-23. [DOI: 10.3390/immuno1040029] [Reference Citation Analysis]
20 Sherry AD, Newman NB, Anderson JL, Osmundson EC. Systemic inflammatory dynamics during chemoradiotherapy predict response, relapse, metastasis, and survival in esophageal carcinoma. J Surg Oncol 2019;121:303-12. [DOI: 10.1002/jso.25793] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
21 Mu Q, Najafi M. Modulation of the tumor microenvironment (TME) by melatonin. Eur J Pharmacol 2021;907:174365. [PMID: 34302814 DOI: 10.1016/j.ejphar.2021.174365] [Reference Citation Analysis]
22 Chen IM, Johansen JS, Theile S, Hjaltelin JX, Novitski SI, Brunak S, Hasselby JP, Willemoe GL, Lorentzen T, Madsen K, Jensen BV, Wilken EE, Geertsen P, Behrens C, Nolsoe C, Hermann KL, Svane IM, Nielsen D. Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC). J Clin Oncol 2022;:JCO2102511. [PMID: 35476508 DOI: 10.1200/JCO.21.02511] [Reference Citation Analysis]
23 Tian Y, Ma J, Jing X, Zhai X, Li Y, Guo Z, Yu J, Zhu H. Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy. Cancer Lett 2022;:215719. [PMID: 35597478 DOI: 10.1016/j.canlet.2022.215719] [Reference Citation Analysis]
24 Halama N, Haberkorn U. The Unmet Needs of the Diagnosis, Staging, and Treatment of Gastrointestinal Tumors. Semin Nucl Med 2020;50:389-98. [PMID: 32768003 DOI: 10.1053/j.semnuclmed.2020.06.003] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Shang S, Liu J, Verma V, Wu M, Welsh J, Yu J, Chen D. Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates. Cancer Commun (Lond) 2021;41:1086-99. [PMID: 34658186 DOI: 10.1002/cac2.12226] [Reference Citation Analysis]
26 Chua KLM, Chu PL, Tng DJH, Soo KC, Chua MLK. Repurposing Proton Beam Therapy through Novel Insights into Tumour Radioresistance. Clin Oncol (R Coll Radiol) 2021;33:e469-81. [PMID: 34509347 DOI: 10.1016/j.clon.2021.08.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zhu N, Yang Y, Wang H, Tang P, Zhang H, Sun H, Gong L, Yu Z. CSF2RB Is a Unique Biomarker and Correlated With Immune Infiltrates in Lung Adenocarcinoma. Front Oncol 2022;12:822849. [PMID: 35574409 DOI: 10.3389/fonc.2022.822849] [Reference Citation Analysis]
28 Wang Y, Jia A, Bi Y, Wang Y, Yang Q, Cao Y, Li Y, Liu G. Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy. Cancers (Basel) 2020;12:E2626. [PMID: 32942545 DOI: 10.3390/cancers12092626] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
29 Wu Q, Wang L, Wei H, Li B, Yang J, Wang Z, Xu J, Zhou YL, Zhang B. Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures. Int Immunopharmacol 2020;83:106477. [PMID: 32278127 DOI: 10.1016/j.intimp.2020.106477] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
30 Nowosielska EM, Cheda A, Pociegiel M, Cheda L, Szymański P, Wiedlocha A. Effects of a Unique Combination of the Whole-Body Low Dose Radiotherapy with Inactivation of Two Immune Checkpoints and/or a Heat Shock Protein on the Transplantable Lung Cancer in Mice. Int J Mol Sci 2021;22:6309. [PMID: 34208396 DOI: 10.3390/ijms22126309] [Reference Citation Analysis]
31 De P, Aske J, Sulaiman R, Dey N. Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance. Cancers 2022;14:1519. [DOI: 10.3390/cancers14061519] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Scarborough JA, Scott JG. Translation of Precision Medicine Research Into Biomarker-Informed Care in Radiation Oncology. Semin Radiat Oncol 2022;32:42-53. [PMID: 34861995 DOI: 10.1016/j.semradonc.2021.09.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 McBride S, Sherman E, Tsai CJ, Baxi S, Aghalar J, Eng J, Zhi WI, McFarland D, Michel LS, Young R, Lefkowitz R, Spielsinger D, Zhang Z, Flynn J, Dunn L, Ho A, Riaz N, Pfister D, Lee N. Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol 2021;39:30-7. [PMID: 32822275 DOI: 10.1200/JCO.20.00290] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 15.0] [Reference Citation Analysis]
34 Xia WY, Feng W, Zhang CC, Shen YJ, Zhang Q, Yu W, Cai XW, Fu XL. Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review. Transl Lung Cancer Res 2020;9:2120-36. [PMID: 33209631 DOI: 10.21037/tlcr-20-827] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Franiak-Pietryga I, Miyauchi S, Kim SS, Sanders PD, Sumner W, Zhang L, Mundt AJ, Califano JA, Sharabi AB. Activated B Cells and Plasma Cells Are Resistant to Radiation Therapy. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02730-9. [PMID: 34474108 DOI: 10.1016/j.ijrobp.2021.08.037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther 2022;7:258. [PMID: 35906199 DOI: 10.1038/s41392-022-01102-y] [Reference Citation Analysis]
37 Nandi A, Chakrabarti R. The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance. Genes Dev 2020;34:1422-38. [PMID: 33872192 DOI: 10.1101/gad.342287.120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
38 Sun JR, Zhang X, Zhang Y. MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1. Cell Mol Biol Lett 2019;24:68. [PMID: 31844419 DOI: 10.1186/s11658-019-0190-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
39 Oweida AJ, Darragh L, Phan A, Binder D, Bhatia S, Mueller A, Court BV, Milner D, Raben D, Woessner R, Heasley L, Nemenoff R, Clambey E, Karam SD. STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer. J Natl Cancer Inst 2019;111:1339-49. [PMID: 30863843 DOI: 10.1093/jnci/djz036] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 18.5] [Reference Citation Analysis]
40 Braun C, Weichhart T. mTOR-dependent immunometabolism as Achilles' heel of anticancer therapy. Eur J Immunol 2021. [PMID: 34648202 DOI: 10.1002/eji.202149270] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Lei Q, Wang D, Sun K, Wang L, Zhang Y. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. Front Cell Dev Biol 2020;8:672. [PMID: 32793604 DOI: 10.3389/fcell.2020.00672] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
42 Li W, Zhan M, Quan Y, Wang H, Hua S, Li Y, Zhang J, Lu L, Cui M. Modulating the tumor immune microenvironment with sunitinib malate supports the rationale for combined treatment with immunotherapy. International Immunopharmacology 2020;81:106227. [DOI: 10.1016/j.intimp.2020.106227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
43 Fu C, Feng S, Wang S, Su X. Development and validation of a prognostic model for esophageal carcinoma based on immune microenvironment using system bioinformatics. Cancer Med 2022. [PMID: 35771026 DOI: 10.1002/cam4.4985] [Reference Citation Analysis]
44 Ma J, Na S, Wang P, Li J, He S, Liu F. miR-626 Inhibition Enhanced the Radiosensitivity to Oral Squamous Cell Carcinoma via the Downregulation of Nuclear Factor Kappa-B Signaling. Cancer Biother Radiopharm 2022. [PMID: 35549438 DOI: 10.1089/cbr.2021.0344] [Reference Citation Analysis]
45 Flavell RR, Evans MJ, Villanueva-Meyer JE, Yom SS. Understanding Response to Immunotherapy Using Standard of Care and Experimental Imaging Approaches. Int J Radiat Oncol Biol Phys 2020;108:242-57. [PMID: 32585333 DOI: 10.1016/j.ijrobp.2020.06.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Chen C, Liu Y, Cui B. Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment. Hum Vaccin Immunother 2021;17:1555-67. [PMID: 33428533 DOI: 10.1080/21645515.2020.1840254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
47 Kim YJ, Kim K, Seo SY, Yu J, Kim IH, Kim HJ, Park CK, Lee KH, Choi J, Song MS, Kim JH. Time-sequential change in immune-related gene expression after irradiation in glioblastoma: next-generation sequencing analysis. Anim Cells Syst (Seoul) 2021;25:245-54. [PMID: 34408813 DOI: 10.1080/19768354.2021.1954550] [Reference Citation Analysis]
48 Vanmeerbeek I, Sprooten J, De Ruysscher D, Tejpar S, Vandenberghe P, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L, Garg AD. Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. Oncoimmunology 2020;9:1703449. [PMID: 32002302 DOI: 10.1080/2162402X.2019.1703449] [Cited by in Crossref: 58] [Cited by in F6Publishing: 41] [Article Influence: 29.0] [Reference Citation Analysis]
49 Huang J, Li JJ. Multiple Dynamics in Tumor Microenvironment Under Radiotherapy. Adv Exp Med Biol 2020;1263:175-202. [PMID: 32588328 DOI: 10.1007/978-3-030-44518-8_10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
50 Liu X, Qiao L. Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review. Front Nutr 2022;9:810472. [PMID: 35399666 DOI: 10.3389/fnut.2022.810472] [Reference Citation Analysis]
51 Werner J, Strobel K, Lehnick D, Rajan GP. Overall Neutrophil-to-Lymphocyte Ratio and SUVmax of Nodal Metastases Predict Outcome in Head and Neck Cancer Before Chemoradiation. Front Oncol 2021;11:679287. [PMID: 34692472 DOI: 10.3389/fonc.2021.679287] [Reference Citation Analysis]
52 Chen S, Ben S, Xin J, Li S, Zheng R, Wang H, Fan L, Du M, Zhang Z, Wang M. The biogenesis and biological function of PIWI-interacting RNA in cancer. J Hematol Oncol 2021;14:93. [PMID: 34118972 DOI: 10.1186/s13045-021-01104-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Nie Z, Pu T, Han Z, Wang C, Pan C, Li P, Ma X, Yao Y, Zhao Y, Wang C, Jiang X, Ding J. Extra Spindle Pole Bodies-Like 1 Serves as a Prognostic Biomarker and Promotes Lung Adenocarcinoma Metastasis. Front Oncol 2022;12:930647. [DOI: 10.3389/fonc.2022.930647] [Reference Citation Analysis]
54 Jiang N, Xie B, Xiao W, Fan M, Xu S, Duan Y, Hamsafar Y, Evans AC, Huang J, Zhou W, Lin X, Ye N, Wanggou S, Chen W, Jing D, Fragoso RC, Dugger BN, Wilson PF, Coleman MA, Xia S, Li X, Sun L, Monjazeb AM, Wang A, Murphy WJ, Kung H, Lam KS, Chen H, Li JJ. Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-29137-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]